Thursday, 28 October 2021

ZyCoV-D 2nd home vaccine to have vaccine drive soon

ZyCoV-D 2nd home vaccine to have vaccine drive soon

On Thursday, officials said at the health ministry’s briefing, ZyCoV-D 2nd home vaccine for Covid-19, ZyCoV-D, will be included in the immunization drive “very shortly,”

And the drive is likely to be open up to 12 years old children and above, and other people are aware of the matter added separately.

India’s drug regulators have granted ZyCoV-D 2nd home vaccine an emergency use authorization after interim clinical trial data showed it was 66% successful in preventing suggesting Covid-19. The trials included volunteers in the 12-18 age group and were among the first doses to be safe and effective on the children group.

Union secretary for health and family welfare Rajesh Bhushan said the government was in talks with the vaccine manufacturer regarding pricing and procurement.

Bhushan said during the media briefing.

“As far as the price of the corona vaccine at which it will be procured is worried, we are in talk with the manufacturers. Since it is a three-dosage vaccine and comes with a needleless structure, it would have a difference pricing gap than the existing vaccines that are being used in the Covid-19 vaccination drive,”

Bhushan added.

“It will be introduced in the programme (Covid-19) very shortly,”

ZyCoV D 2nd home vaccine to have vaccine drive soon 1unsplash image

Read More : The zyCov-D vaccine gets approval in India for emergency use

A person aware of the matter separately said the vaccine would likely be offered to 12-18 year-olds as well.

Union health minister Mansukh Mandaviya, while announcing that India will restart vaccine exports in the quarter beginning October, said in a statement on September 20 that manufacturers were going to make nearly 300 million doses available for use in October.

Children in at least 50 countries have begun giving doses. In most instances, children above the age of 12 are vaccinating. The shots being using for these ages are typically the Pfizer-BioNTech and Moderna doses – both have shown to be safe in children, and their efficacy has been establishing.

In India, Covaxin and the Novavax vaccine makers are carrying out supplementary––also known as bridging -- trials in children. In adults, India has primarily been using Covishield and Covaxin.

Said by a second senior government official aware of the matter, requesting anonymity.

“The production is going to go up further in the next quarter with the Zydus vaccine doses also getting added in some time. The supply lines have been streamlined...,”

Follow Us

Popular Post

School in Delhi to re-open from 1st November

School in Delhi to re-open from 1st November

Farhan Sayyed Oct 27, 2021 Politics

After more than eighteen months, all schools in Delhi will be permitted to re-open for all classes, including at the primary level—from 1st November. ...